

## CDC Immunization Information Systems (IIS) Vaccine Code Set Release Notes

**Vaccine Code Set Update Publication Date: April 16, 2026**

*The individual filenames included in this distribution contain the publication date (20260416)*

**Release Notes:** Release notes provide a technical summary of the updates made to vaccine code sets and crosswalks. This code set release includes updates for all regular vaccine-related codes. It does not include updates to codes for Vaccine Information Statements (VIS).

**General Note Regarding This Release:** Codes with “Last Update” dates from February 12, 2026, and before April 16, 2026, reflect the changes and additions in this release.

This release includes vaccine code set updates related to the following:

- 1. FLUZONE Southern Hemisphere 2026 Vaccine Codes Added**
- 2. Sanofi NDC Labeler Updated**
- 3. Other NDC Codes Updated**

Detailed technical release notes are provided upon the publication of a vaccine code set. You may find the date of the most recent code set publication and a downloadable PDF version of the most recent release notes on the page found here: [Vaccine Data Code Sets | Immunization Information Systems \(IIS\) | CDC](#).

You may subscribe to receive future email vaccine code set updates via the sign up at the bottom of the webpage ([Vaccine Data Code Sets | Immunization Information Systems \(IIS\) | CDC](#)).

### Vaccine Code Set Updates – Details

#### 1. FLUZONE Southern Hemisphere 2026 Vaccine Codes Added

New NDCs have been added for the Southern Hemisphere 2026 vaccine season. These vaccines are all trivalent. A new CVX code and a new Product Tradename record have been added for the high-dose product. NDC pairs and associated codes are shown below.

Sale Proprietary Name	Sale Labeler	Sale NDC11	Sale NDC10	SalePackForm	Use NDC11	Use NDC10	UseUnitPack Form	CVX Code	CVX Short Description	MVX Code
FLUZONE HD TIV SH 2026	Sanofi Vaccines US Inc.	49281-0016-50	49281-016-50	PACKAGE, 10 SYRINGE	49281-0016-88	49281-016-88	SYRINGE, 0.5 mL	337	Influenza, Southern Hemisphere, high-dose, trivalent, PF	PMC
FLUZONE TIV SH 2026	Sanofi Vaccines US Inc.	49281-0626-50	49281-626-50	PACKAGE, 10 SYRINGE	49281-0626-88	49281-626-88	SYRINGE, 0.5 mL	331	Influenza, Southern Hemisphere, trivalent, PF	PMC

To support the new trivalent 2026 Southern Hemisphere high-dose vaccine, the following new codes have been added:

- **New CVX code 337** has been added and associated to Vaccine Group “FLU”

## CDC Immunization Information Systems (IIS) Vaccine Code Set Release Notes

Short Description: “Influenza, Southern Hemisphere, high-dose, trivalent, PF”

Long Description: “Influenza, Southern Hemisphere, high-dose, split virus, trivalent, 0.5 mL, injectable, preservative free”

- **New Product Name** “FLUZONE High-Dose Trivalent Southern Hemisphere” has been added and associated to CVX 337 and MVX PMC

Note that the seasonal influenza crosswalk tables have also been updated to reflect the 2026 Southern Hemisphere vaccines and the Sanofi NDC Labeler changes. [Fall Season Respiratory Vaccine Codes | Immunization Information Systems \(IIS\) | CDC](#).

### 2. Sanofi NDC Labeler Updated

The FDA listed Sale Labeler name has been updated from “Sanofi Pasteur, Inc.” to “Sanofi Vaccines US Inc.” for the following NDC pairs. No other changes have been made to the NDC codes or to the MVX code mapping. The MVX code remains as PMC.

Sale Proprietary Name	Sale Labeler	Sale NDC11	Sale NDC10	Use NDC11	Use NDC10
YF-VAX	Sanofi Vaccines US Inc.	49281-0915-01	49281-915-01	49281-0915-58	49281-915-58
YF-VAX	Sanofi Vaccines US Inc.	49281-0915-05	49281-915-05	49281-0915-68	49281-915-68
FLUZONE TRIVALENT NORTHERN HEMISPHERE	Sanofi Vaccines US Inc.	49281-0643-15	49281-643-15	49281-0643-78	49281-643-78
Dengvaxia	Sanofi Vaccines US Inc.	49281-0605-01	49281-605-01	49281-0606-58	49281-606-58
Menactra	Sanofi Vaccines US Inc.	49281-0589-05	49281-589-05	49281-0589-58	49281-589-58
MenQuadfi	Sanofi Vaccines US Inc.	49281-0590-05	49281-590-05	49281-0590-58	49281-590-58
MenQuadfi	Sanofi Vaccines US Inc.	49281-0590-01	49281-590-01	49281-0590-58	49281-590-58
MenQuadfi	Sanofi Vaccines US Inc.	49281-0590-10	49281-590-10	49281-0590-58	49281-590-58
Typhim Vi	Sanofi Vaccines US Inc.	49281-0790-20	49281-790-20	49281-0790-38	49281-790-38
Typhim Vi	Sanofi Vaccines US Inc.	49281-0790-51	49281-790-51	49281-0790-88	49281-790-88
ActHIB	Sanofi Vaccines US Inc.	49281-0545-03	49281-545-03	49281-0547-58	49281-547-58
IMOVAX RABIES	Sanofi Vaccines US Inc.	49281-0252-51	49281-252-51	49281-0246-58	49281-246-58
FLUZONE TRIVALENT NORTHERN HEMISPHERE	Sanofi Vaccines US Inc	49281-0425-50	49281-425-50	49281-0425-88	49281-425-88
FLUZONE TRIVALENT NORTHERN HEMISPHERE	Sanofi Vaccines US Inc	49281-0643-15	49281-643-15	49281-0643-78	49281-643-78

### 3. Other NDC Codes Updated

The following NDC codes had minor changes to fields not visible in the published tables that resulted in changes to the date of last update.

Sale Proprietary Name	Sale Labeler	Sale NDC11	Sale NDC10	Use NDC11	Use NDC10
HEPLISAV-B	Dynavax Technologies Corporation	43528-0003-05	43528-003-05	43528-0003-01	43528-003-01

## CDC Immunization Information Systems (IIS) Vaccine Code Set Release Notes

### Access to CDC Vaccine Code Sets

CDC provides additional methods to access the vaccine codes in addition to the files and content found on CDC's Vaccine Code Sets website here: [Vaccine Data Code Sets | Immunization Information Systems \(IIS\) | CDC](#).

You are encouraged to explore the following additional methods available here: [Information on Vaccine Code Set Access Options | Immunization Information Systems \(IIS\) | CDC](#):

- The **Viewpoint Vaccine Code Set Browser** provides dynamic browse and search capabilities against the entire Vaccine Code Set.
- The **Runtime REST Web Service** provides improved access to Vaccine Code Sets data by providing a way for development teams and other technical users to query and receive vaccine code data via API.
- The **Content Cloud Portal** provides delivery and download of desired reports. Access and file subscriptions are managed by registration.

For questions or need further assistance with any of the additional methods mentioned above please email [iisinfo@cdc.gov](mailto:iisinfo@cdc.gov).